Related Experiment Video
Updated: May 24, 2026
07:32
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
FGF23 as a novel therapeutic target.
Takashi Shimada1, Seiji Fukumoto
1Kyowa Hakko Kirin Co., Ltd, Tokyo, Japan. takashi.shimada@kyowa-kirin.co.jp
Advances in Experimental Medicine and Biology
|March 8, 2012
Summary
Fibroblast growth factor (FGF) 23 is crucial for phosphate and vitamin D balance. Dysregulation of FGF23 causes metabolic bone diseases, suggesting targeted therapies like inhibition or replacement could be beneficial.
Area of Science:
- Endocrinology
- Metabolic Bone Diseases
- Mineral Metabolism
Background:
- Fibroblast growth factor (FGF) 23 is a key hormone regulating phosphate and vitamin D homeostasis.
- Imbalances in FGF23 activity, whether excess or deficiency, lead to significant metabolic bone disorders.
- Understanding FGF23's role is critical for diagnosing and treating hypophosphatemic conditions.
Purpose of the Study:
- To explore the therapeutic potential of modulating FGF23 activity in metabolic bone diseases.
- To highlight FGF23-dependent diseases as targets for novel treatment strategies.
- To review current knowledge and future directions in FGF23-regulated therapies.
Main Methods:
- Analysis of circulating FGF23 levels in patients with hypophosphatemic rickets and osteomalacia.
- Evaluation of a mouse disease model to validate FGF23 inhibition as a therapeutic concept.
- Review of existing literature on FGF23-related pathophysiology and therapeutic interventions.
Main Results:
- Several hypophosphatemic diseases were identified as FGF23-dependent.
- Preliminary studies in a mouse model supported the efficacy of FGF23 inhibition.
- Recombinant FGF23 replacement therapy emerged as a potential treatment for FGF23 deficiency disorders.
Conclusions:
- Targeting FGF23 activity presents a promising therapeutic avenue for specific metabolic bone diseases.
- FGF23 inhibition may benefit conditions with excess FGF23 activity.
- FGF23 replacement therapy is a potential strategy for FGF23 loss-of-function disorders.
- Further research is needed to validate these therapeutic concepts in clinical settings.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Transducer Mechanism: G Protein–Coupled Receptors
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
GPCRs are also called heptahelical, 7TM, or...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...